免疫肿瘤药物市场规模、份额、成长分析（按治疗类型、疾病类型、分销管道和地区）-产业预测，2025-2032

2023年，免疫肿瘤药物的全球市场规模为230.2亿美元，从2024年的272.6亿美元成长到2032年的1052.6亿美元，预计在预测期内（2025-2032年）将以复合年增长率增长。 18.4%。

免疫肿瘤学 (IO) 药物因其个人化方法而在癌症治疗中取得了进展，该方法根据患者的遗传特征和肿瘤特征量身定制治疗。与传统治疗相比，这种有针对性的策略可以最大限度地减少副作用并改善患者的整体治疗结果。 IO 药物的主要优点包括提高存活率、减少副作用以及长期缓解的可能性。这是因为该药物能够刺激免疫系统选择性地识别和破坏癌细胞，从而保护健康组织。 IO 疗法的持续疗效非常显着，患者报告由于併发症较少而改善了生活质量，并且它对多种癌症（包括黑色素瘤和肺癌）患者显示出持续疗效。这种能力代表了有效管理癌症作为一种慢性疾病并改善患者长期福祉的变革性转变。

目录

介绍

• 研究目的
• 调查范围
• 定义

调查方法

• 资讯采购
• 二手资料和主要资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 按细分市场的机会分析

市场动态及展望

• 市场概况
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制因素和挑战
• 波特的分析

主要市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024）
• PESTEL分析
• 总体经济指标
• 价值链分析
• 价格分析
• 监管分析
• 案例研究分析
• 专利分析

按治疗类型分類的免疫肿瘤药物市场规模

• 市场概况
• 免疫查核点抑制剂
• 免疫系统调节剂
• 癌症疫苗
• 溶瘤病毒
• 其他的

按疾病类型分類的免疫肿瘤药物市场规模

• 市场概况
• 恶性黑色素瘤
• 肺癌
• 血癌
• 肾臟细胞癌
• 摄护腺癌
• 膀胱癌
• 其他的

免疫肿瘤药物市场规模：依通路划分

• 市场概况
• 医院药房
• 零售药房
• 网路药房

免疫肿瘤药物市场规模

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东/非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东/非洲

竞争资讯

• 前5名企业对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市场占有率分析（2024年）
• 主要企业简介
  • 公司简介
  • 产品系列分析
  • 按细分市场分類的份额分析
  • 收益与前一年同期比较（2022-2024）

主要企业简介

• Coloplast Corp（Denmark）
• Bristol Myers Squibb Company（US）
• Novartis AG（Switzerland）
• F. Hoffmann-La Roche Ltd.（Switzerland）
• Merck & Co., Inc.（US）
• GSK Plc.（UK）
• Eli Lilly and Company（US）
• Fresenius Kabi AG（Germany）
• Pfizer Inc.（US）
• AbbVie Inc.（US）
• Genentech Inc.（US）
• Sanofi（France）
• AstraZeneca（UK）
• Bayer AG（Germany）
• Bluebird Bio, Inc.（US）
• Regeneron Pharmaceuticals, Inc.（US）
• Amgen Inc.（US）
• Johnson & Johnson（US）
• Merck KGaA（Germany）
• Ipsen（France）

结论和建议

Global Immuno-Oncology Drugs Market size was valued at USD 23.02 billion in 2023 and is poised to grow from USD 27.26 billion in 2024 to USD 105.26 billion by 2032, growing at a CAGR of 18.4% during the forecast period (2025-2032).

Immuno-Oncology (IO) drugs are gaining traction in cancer treatment due to their personalized approach, which aligns therapy with patients' genetic profiles and tumor characteristics. This targeted strategy minimizes side effects compared to conventional treatments, enhancing overall patient outcomes. Key advantages of IO drugs include increased survival rates, reduced adverse effects, and potential for long-term remission, driven by the drugs' ability to stimulate the immune system to selectively identify and destroy cancer cells, sparing healthy tissue. As patients report improved quality of life with fewer complications, the enduring effectiveness of IO therapies is noteworthy-showing sustained responses in patients with various cancers, including melanoma and lung cancer. This capability signifies a transformative shift towards managing cancer as a chronic condition effectively and improving long-term patient welfare.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Immuno-Oncology Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Immuno-Oncology Drugs Market Segmental Analysis

Global Immuno-Oncology Drugs Market is segmented by treatment type, disease type, distribution channel and region. Based on treatment type, the market is segmented into immune checkpoint inhibitors, immune system modulators, cancer vaccines, oncolytic virus and others. Based on disease type, the market is segmented into melanoma, lung cancer, blood cancer, renal cell carcinoma, prostate cancer, bladder cancer and others. Based on distribution channel, the market is segmented into hospital pharmacies, retail pharmacies and online pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Immuno-Oncology Drugs Market

One of the primary catalysts for growth in the Global Immuno-Oncology Drugs market is the approval of these drugs by regulatory agencies. The endorsement from entities such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) is crucial, as it validates the safety and efficacy of the drugs, allowing them to be marketed and utilized in clinical settings. These approvals signify a positive outlook for the market, attracting investments from pharmaceutical companies eager to develop new immuno-oncology treatments. As more drugs receive regulatory green lights, healthcare providers gain access to innovative therapies, ultimately improving patient outcomes and fostering further advancements in the field. This dynamic underscores the vital role regulatory approvals play in shaping the immuno-oncology landscape.

Restraints in the Global Immuno-Oncology Drugs Market

The growth of the global immuno-oncology drugs market faces significant challenges primarily due to their high costs. These treatments are often prohibitively expensive, creating financial burdens for both patients and healthcare systems. The exorbitant prices can deter adoption, particularly in regions with limited access to affordable healthcare, adversely impacting market expansion. Moreover, the steep costs may dissuade insurance companies and government healthcare programs from providing coverage, leading to further restrictions on patient access to these essential therapies. Consequently, the high pricing of immuno-oncology drugs stands as a substantial barrier to market growth and patient treatment options.

Market Trends of the Global Immuno-Oncology Drugs Market

The Global Immuno-Oncology (IO) Drugs market is witnessing a significant trend towards the development and integration of biomarkers, enhancing the precision of cancer treatments. Biomarkers enable healthcare professionals to identify patients who are most likely to benefit from immuno-oncology therapies, facilitating personalized treatment approaches. This trend not only improves patient selection and therapeutic outcomes but also minimizes adverse effects by excluding those unlikely to respond. As research advances in identifying new biomarkers, the IO drug market is poised for growth, driving innovations that lead to safer and more effective cancer treatments and ultimately transforming patient care landscapes worldwide.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Analysis
• Case Study Analysis
• Patent Analysis

Global Immuno-Oncology Drugs Market Size by Treatment Type & CAGR (2025-2032)

• Market Overview
• Immune Checkpoint Inhibitors
• Immune System Modulators
• Cancer Vaccines
• Oncolytic Virus
• Others

Global Immuno-Oncology Drugs Market Size by Disease Type & CAGR (2025-2032)

• Market Overview
• Melanoma
• Lung Cancer
• Blood Cancer
• Renal Cell Carcinoma
• Prostate Cancer
• Bladder Cancer
• Others

Global Immuno-Oncology Drugs Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Immuno-Oncology Drugs Market Size & CAGR (2025-2032)

• North America (Treatment Type, Disease Type, Distribution Channel)
  • US
  • Canada
• Europe (Treatment Type, Disease Type, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Treatment Type, Disease Type, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Treatment Type, Disease Type, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Treatment Type, Disease Type, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Coloplast Corp (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb Company (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GSK Plc. (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fresenius Kabi AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Genentech Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bluebird Bio, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneron Pharmaceuticals, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck KGaA (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ipsen (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations